Utidelone and Capecitabine for triple-negative breast cancer brain metastases
Part of Cancer, Skin clinical trials.
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have triple-negative breast cancer (TNBC) that has spread to the brain, and the brain tumors are new or have grown after previous treatment.
- You can have an MRI with contrast to check your brain tumors.
- You have previously received a taxane (like paclitaxel) or an anthracycline (like doxorubicin) for your breast cancer.
- You are in generally good health (ECOG score 0–2) and have normal organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
This trial tests whether adding a study drug called UTD1 to capecitabine can shrink or control breast cancer that has spread to the brain. It’s for people with HER2-negative metastatic breast cancer who have brain metastases and meet specific safety and lab requirements.
This trial tests a combination of two oral chemotherapy drugs (Utidelone and Capecitabine) for women with triple-negative breast cancer that did not fully disappear after standard chemo before surgery. The goal is to see if this treatment can lower the chance of the cancer coming back.
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
This trial tests a new drug called sacituzumab tirumotecan for people with triple-negative breast cancer that has spread to the brain. It may help shrink brain tumors and improve outcomes for those who have not responded to previous treatments.
This trial tests a combination of two anti-cancer drugs for people with HER2-positive breast cancer that has spread to the brain and has not responded to a prior antibody-drug conjugate treatment. The goal is to see if this combination can shrink or control brain metastases.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.